Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma

Marc Sorigue; Juan Manuel Sancho; Alberto Pineda; Olga Garcia; David Lopez; Miriam Moreno; Gustavo Tapia; Montse Batlle; Christelle Ferra; Susanna Vives; Gladys Ibarra; Evarist Feliu; Josep Maria Ribera

doi:10.1016/j.leukres.2017.05.001

Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma

Marc Sorigue, Juan Manuel Sancho, Alberto Pineda, Olga Garcia, David Lopez, Miriam Moreno, Gustavo Tapia, Montse Batlle, Christelle Ferra, Susanna Vives, Gladys Ibarra, Evarist Feliu, Josep Maria Ribera

Producció científica: Contribució a revista › Article › Recerca › Avaluat per experts

3 Cites (Scopus)

Resum

© 2017 Elsevier Ltd Nephrotoxicity is a well-known side effect of platinum-based chemotherapy. We retrospectively assessed the incidence and prognostic impact of nephrotoxicity with ESHAP rescue chemotherapy in 74 lymphoma patients (61 aggressive lymphomas). A higher incidence of nephrotoxicity (estimated glomerular filtration rate <60 mL/min) was found when ESHAP was administred on an outpatient vs. inpatient basis (14/39 vs. 4/35). Patients submitted to ASCT with renal failure had a lower overall survival (OS) than those with normal renal function (2-yr OS probability [95%CI]: 88% [77%–99%] vs. 50% [22%–78%]). Outpatient administration of ESHAP may not be optimal for all patients and the impact of ESHAP-induced renal failure on ASCT outcomes in lymphoma needs to be assessed in prospective studies.

Idioma original	Anglès
Pàgines (de-a)	98-101
Revista	Leukemia Research
Volum	58
DOIs	https://doi.org/10.1016/j.leukres.2017.05.001
Estat de la publicació	Publicada - 1 de jul. 2017

Accés al document

10.1016/j.leukres.2017.05.001

Com citar-ho

@article{02885e1cf02c4b8bac2959120da4a0c4,

title = "Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma",

abstract = "{\textcopyright} 2017 Elsevier Ltd Nephrotoxicity is a well-known side effect of platinum-based chemotherapy. We retrospectively assessed the incidence and prognostic impact of nephrotoxicity with ESHAP rescue chemotherapy in 74 lymphoma patients (61 aggressive lymphomas). A higher incidence of nephrotoxicity (estimated glomerular filtration rate <60 mL/min) was found when ESHAP was administred on an outpatient vs. inpatient basis (14/39 vs. 4/35). Patients submitted to ASCT with renal failure had a lower overall survival (OS) than those with normal renal function (2-yr OS probability [95%CI]: 88% [77%–99%] vs. 50% [22%–78%]). Outpatient administration of ESHAP may not be optimal for all patients and the impact of ESHAP-induced renal failure on ASCT outcomes in lymphoma needs to be assessed in prospective studies.",

keywords = "Autologous stem cell transplantation, ESHAP, Lymphoma, Nephrotoxicity, Platinum, Survival",

author = "Marc Sorigue and Sancho, {Juan Manuel} and Alberto Pineda and Olga Garcia and David Lopez and Miriam Moreno and Gustavo Tapia and Montse Batlle and Christelle Ferra and Susanna Vives and Gladys Ibarra and Evarist Feliu and Ribera, {Josep Maria}",

year = "2017",

month = jul,

day = "1",

doi = "10.1016/j.leukres.2017.05.001",

language = "English",

volume = "58",

pages = "98--101",

journal = "Leukemia Research",

issn = "0145-2126",

publisher = "Elsevier Limited",

}

TY - JOUR

T1 - Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma

AU - Sorigue, Marc

AU - Sancho, Juan Manuel

AU - Pineda, Alberto

AU - Garcia, Olga

AU - Lopez, David

AU - Moreno, Miriam

AU - Tapia, Gustavo

AU - Batlle, Montse

AU - Ferra, Christelle

AU - Vives, Susanna

AU - Ibarra, Gladys

AU - Feliu, Evarist

AU - Ribera, Josep Maria

PY - 2017/7/1

Y1 - 2017/7/1

N2 - © 2017 Elsevier Ltd Nephrotoxicity is a well-known side effect of platinum-based chemotherapy. We retrospectively assessed the incidence and prognostic impact of nephrotoxicity with ESHAP rescue chemotherapy in 74 lymphoma patients (61 aggressive lymphomas). A higher incidence of nephrotoxicity (estimated glomerular filtration rate <60 mL/min) was found when ESHAP was administred on an outpatient vs. inpatient basis (14/39 vs. 4/35). Patients submitted to ASCT with renal failure had a lower overall survival (OS) than those with normal renal function (2-yr OS probability [95%CI]: 88% [77%–99%] vs. 50% [22%–78%]). Outpatient administration of ESHAP may not be optimal for all patients and the impact of ESHAP-induced renal failure on ASCT outcomes in lymphoma needs to be assessed in prospective studies.

AB - © 2017 Elsevier Ltd Nephrotoxicity is a well-known side effect of platinum-based chemotherapy. We retrospectively assessed the incidence and prognostic impact of nephrotoxicity with ESHAP rescue chemotherapy in 74 lymphoma patients (61 aggressive lymphomas). A higher incidence of nephrotoxicity (estimated glomerular filtration rate <60 mL/min) was found when ESHAP was administred on an outpatient vs. inpatient basis (14/39 vs. 4/35). Patients submitted to ASCT with renal failure had a lower overall survival (OS) than those with normal renal function (2-yr OS probability [95%CI]: 88% [77%–99%] vs. 50% [22%–78%]). Outpatient administration of ESHAP may not be optimal for all patients and the impact of ESHAP-induced renal failure on ASCT outcomes in lymphoma needs to be assessed in prospective studies.

KW - Autologous stem cell transplantation

KW - ESHAP

KW - Lymphoma

KW - Nephrotoxicity

KW - Platinum

KW - Survival

U2 - 10.1016/j.leukres.2017.05.001

DO - 10.1016/j.leukres.2017.05.001

M3 - Article

SN - 0145-2126

VL - 58

SP - 98

EP - 101

JO - Leukemia Research

JF - Leukemia Research

ER -

Incidence and prognostic significance of nephrotoxicity in patients receiving eshap as salvage therapy for lymphoma

Resum

Accés al document

Fingerprint

Com citar-ho